Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

NCT04318704 is registered in ClinicalTrials.gov with Algernon Pharmaceuticals as lead sponsor.

NCT NCT04318704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04318704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
Lead sponsor
Algernon Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
July 29, 2020
Completion date
May 10, 2022
Enrollment
20 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis